{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T04:31:03Z","timestamp":1786336263837,"version":"build-2736575974"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100019081","name":"Science and Technology Program of Hunan Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019081","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>SMARCA4-deficient non-small cell lung cancer (SMARCA4-dNSCLC) is an uncommon malignant epithelial neoplasm originating in the lung, characterized by poorly differentiated and highly invasive pathological features, and associated with a poor prognosis. Currently, there is no standardized treatment protocol for SMARCA4-dNSCLC, as it generally exhibits a poor response to conventional chemotherapy regimens. Furthermore, the absence of typical driver gene mutations in lung cancer renders it insensitive to targeted therapies. We report the case of a 49-year-old Asian male patient with stage IV non-small cell lung cancer exhibiting SMARCA4 deficiency, who demonstrated a rapid response following treatment with a combination of nab-Paclitaxel, cisplatin, and bevacizumab. However, the patient ultimately experienced treatment failure due to disease progression from brain metastases, resulting in an overall survival (OS) of approximately 12 months. This case demonstrates the complicated clinical features of SMARCA4-deficient lung cancer, enriches the limited relevant clinical literature, and provides supplementary clinical data for this rare tumor subtype. While patients with SMARCA4-deficient lung cancer may benefit from chemotherapy combined with anti-angiogenic targeted therapy, the overall prognosis remains poor.<\/jats:p>","DOI":"10.3389\/fonc.2026.1901621","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T04:22:57Z","timestamp":1786335777000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Advanced non-small cell lung cancer with SMARCA4 deficiency: a case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Jingjing","family":"Chai","sequence":"first","affiliation":[{"name":"Department of Oncology, Taihe Hospital, Hubei University of Medicine","place":["Shiyan, Hubei, China"]},{"name":"Shiyan Key Laboratory of Cancer Therapy Resistance and Clinical Translational Study","place":["Shiyan, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Gong","sequence":"additional","affiliation":[{"name":"Department of Oncology, Taihe Hospital, Hubei University of Medicine","place":["Shiyan, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Gong","sequence":"additional","affiliation":[{"name":"Department of Oncology, Taihe Hospital, Hubei University of Medicine","place":["Shiyan, Hubei, China"]},{"name":"Shiyan Key Laboratory of Cancer Therapy Resistance and Clinical Translational Study","place":["Shiyan, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lurun","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Taihe Hospital, Hubei University of Medicine","place":["Shiyan, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinzhou","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Oncology, Taihe Hospital, Hubei University of Medicine","place":["Shiyan, Hubei, China"]},{"name":"Shiyan Key Laboratory of Cancer Therapy Resistance and Clinical Translational Study","place":["Shiyan, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiguo","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Oncology, Taihe Hospital, Hubei University of Medicine","place":["Shiyan, Hubei, China"]},{"name":"Shiyan Key Laboratory of Cancer Therapy Resistance and Clinical Translational Study","place":["Shiyan, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Xiong","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Disease Diagnosis and Treatment Center, Taihe Hospital, Hubei University of Medicine","place":["Shiyan, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Oncology, Taihe Hospital, Hubei University of Medicine","place":["Shiyan, Hubei, China"]},{"name":"Shiyan Key Laboratory of Cancer Therapy Resistance and Clinical Translational Study","place":["Shiyan, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1053\/j.semdp.2021.06.001","article-title":"Recent updates on thoracic SMARCA4-deficient undifferentiated tumors","volume":"38","author":"Nambirajan","year":"2021","journal-title":"Semin Diagn Pathol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6083","article-title":"Clinical characteristics and prognostic analysis of SMARCA4-deficient non-small cell lung cancer","volume":"12","author":"Liang","year":"2023","journal-title":"Cancer Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.anndiagpath.2025.152499","article-title":"Clinical and pathological characteristics and prognostic factors of SMARCA4-deficient non-small cell lung cancer","volume":"78","author":"Zhang","year":"2025","journal-title":"Ann Diagn Pathol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.11.003","article-title":"The 2021 WHO classification of lung tumors: Impact of advances since 2015","volume":"17","author":"Nicholson","year":"2022","journal-title":"J Thorac Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-023-02773-9","article-title":"The role of chromatin remodeler SMARCA4\/BRG1 in brain cancers: a potential therapeutic target","volume":"42","author":"Navickas","year":"2023","journal-title":"Oncogene"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25063237","article-title":"Clinical characteristics and prognostic analysis of SMARCA4-deficient non-small cell lung cancer","volume":"25","author":"Longo","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2019-0633-OA","article-title":"SMARCA4\/BRG1-deficient non-small cell lung carcinomas: a case series and review of the literature","volume":"145","author":"Nambirajan","year":"2021","journal-title":"Arch Pathol Lab Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"513","DOI":"10.3892\/ol.2023.14100","article-title":"SMARCA4-deficient non-small cell lung cancer with an EGFR mutation: a case report","volume":"26","author":"Sun","year":"2023","journal-title":"Oncol Lett"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3238\/arztebl.2013.0603","article-title":"The CARE guidelines: consensus-based clinical case reporting guideline development","volume":"110","author":"Gagnier","year":"2013","journal-title":"Dtsch Arztebl Int"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq020","article-title":"Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)","volume":"21","author":"Reck","year":"2010","journal-title":"Ann Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl104","article-title":"A novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer","volume":"17","author":"Green","year":"2006","journal-title":"Ann Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e41128","article-title":"The impact of SMARCA4 loss in non-small cell lung cancer therapy","volume":"11","author":"Lombardi","year":"2024","journal-title":"Heliyon"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.70022","article-title":"SMARCA4 deficiency in lung cancer: From signaling pathway to potential therapeutic targets","volume":"64","author":"Zhang","year":"2025","journal-title":"Genes Chromosomes Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.pathol.2023.12.414","article-title":"SMARCA4 deficiency and mutations are frequent in large cell lung carcinoma and are prognostically significant","volume":"56","author":"Cheung","year":"2024","journal-title":"Pathology"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.86338","article-title":"Muscle metastasis as an atypical presentation of non-small cell lung cancer: a case report and literature review","volume":"17","author":"Rezzoug","year":"2025","journal-title":"Cureus"},{"key":"B16","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1186\/s13256-024-04773-z","article-title":"BRAF mutant PD-L1 positive metastatic musculoskeletal lesions from primary lung adenocarcinoma treated with combination vemurafenib and pembrolizumab: a case report","volume":"18","author":"Ngelangel","year":"2024","journal-title":"J Med Case Rep"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1329636","article-title":"GP60 and SPARC as albumin receptors: key targeted sites for the delivery of antitumor drugs","volume":"15","author":"Ji","year":"2024","journal-title":"Front Pharmacol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S88023","article-title":"Albumin-bound paclitaxel in solid tumors: clinical development and future directions","volume":"9","author":"Kundranda","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.03.027","article-title":"Phase 3 trial comparing nanoparticle albumin-bound paclitaxel with docetaxel for previously treated advanced NSCLC","volume":"16","author":"Yoneshima","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1186\/s12916-024-03697-1","article-title":"Efficacy and safety of nanoparticle albumin-bound paclitaxel plus carboplatin as neoadjuvant chemotherapy for stages III-IV, unresectable ovarian cancer: a single-arm, open-label, phase Ib\/II study","volume":"22","author":"Yin","year":"2024","journal-title":"BMC Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.4103\/jcrt.jcrt_792_22","article-title":"Cisplatin-based combination therapy for cancer","volume":"19","author":"Minerva","year":"2023","journal-title":"J Cancer Res Ther"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.7150\/thno.46460","article-title":"Cisplatin prevents breast cancer metastasis through blocking early EMT and retards cancer growth together with paclitaxel","volume":"11","author":"Wang","year":"2021","journal-title":"Theranostics"},{"key":"B23","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1126\/science.1104819","article-title":"Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy","volume":"307","author":"Jain","year":"2005","journal-title":"Science"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000026862","article-title":"Maintenance treatment of combination with bevacizumab vs single agent for advanced non-squamous non-small cell lung cancer: a systematic review and meta-analysis","volume":"100","author":"Kong","year":"2021","journal-title":"Med (Baltimore)"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-21-240","article-title":"Bevacizumab plus platinum-based chemotherapy in advanced non-squamous non-small-cell lung cancer: a randomized, open-label phase 2 study (CLEAR)","volume":"10","author":"Udagawa","year":"2021","journal-title":"Transl Lung Cancer Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2010.09.006","article-title":"Epigenetic antagonism between polycomb and SWI\/SNF complexes during oncogenic transformation","volume":"18","author":"Wilson","year":"2010","journal-title":"Cancer Cell"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1080\/13543776.2024.2338111","article-title":"Synthetic lethality: targeting SMARCA2 ATPase in SMARCA4-deficient tumors - a review of patent literature from 2019-30 June 2023","volume":"34","author":"Reichl","year":"2024","journal-title":"Expert Opin Ther Pat"},{"key":"B28","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41420-025-02306-1","article-title":"PARP inhibition-associated heterochromatin confers increased DNA replication stress and vulnerability to ATR inhibition in SMARCA4-deficient cells","volume":"11","author":"Yano","year":"2025","journal-title":"Cell Death Discov"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgaf002","article-title":"SMARCA4\/BRG1 deficiency induces a targetable dependence on oxidative phosphorylation in clear cell renal cell carcinoma","volume":"46","author":"Fang","year":"2025","journal-title":"Carcinogenesis"},{"key":"B30","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/s41467-018-06958-9","article-title":"CDK4\/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary","volume":"10","author":"Xue","year":"2019","journal-title":"Nat Commun"},{"key":"B31","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s13059-026-04080-4","article-title":"The SMARCA4 subunit of the SWI\/SNF complex prevents genome instability at G quadruplexes","volume":"27","author":"Harrod","year":"2026","journal-title":"Genome Biol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1901621\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T04:22:58Z","timestamp":1786335778000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1901621\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,10]]},"references-count":31,"alternative-id":["10.3389\/fonc.2026.1901621"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1901621","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,10]]},"article-number":"1901621"}}